PLX · Protalix BioTherapeutics, Inc.
$2.31
+0.09 (+3.83%)
At close · Aug 17
Market Cap
$178.87M
Shares
80.57M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dror Bashan | President and Chief Executive Officer | $2,684,941 |
| Eyal Rubin | Senior Vice President and Chief Financial Officer | $1,029,035 |
| Yaron Naos | Senior Vice President, Operations | $776,369 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dror Bashan | President and Chief Executive Officer | $1,468,296 |
| Eyal Rubin | Senior Vice President and Chief Financial Officer | $1,058,281 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dror Bashan | President and Chief Executive Officer | $1,157,699 |
| Eyal Rubin | Senior Vice President, Chief Financial Officer | $836,824 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dror Bashan | President and Chief Executive Officer | $1,341,952 |
| Eyal Rubin | Senior Vice President, Chief Financial Officer | $920,099 |
| Einat Brill Almon | Senior Vice President, Chief Development Officer | $884,666 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Eyal Rubin | Vice President and Chief Financial Officer | Resigned | 2025-07-21 |
| Gilad Mamlok | Senior Vice President and Chief Financial Officer | Appointed | 2025-07-21 |
| Eyal Rubin | Sr. Vice President and Chief Financial Officer | Resigned | 2025-04-23 |
| Zeev Bronfeld | Chairman of the Board | Retired | 2023-09-12 |
| Eliot Richard Forster | Chairman of the Board of Directors | Appointed | 2023-09-12 |
| Shmuel Ben Zvi, Ph.D. | Board of Directors | Appointed | 2022-06-30 |
Key facts
CIK
1006281
CUSIP
74365A309
13F (30d)
98 filings
96 filers
Visit website
Investor relations